Safety and Efficacy of Aficamten in Patients With Non-obstructive Hypertrophic Cardiomyopathy: A 36-week Analysis From FOREST-HCM

SEQUOIA-HCM: Enhancing Exercise Response in Obstructive Hypertrophic Cardiomyopathy

SEQUOIA-HCM: Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy

SEQUOIA-HCM: Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Efficacy and Safety of Aficamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

Efficacy and Safety of Aficamten in the First Cohort of Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy Completing 48-Week Follow-up: Findings From FOREST-HCM

Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Aficamten and its Metabolites

Drug–Drug Interaction Study to Evaluate the Effect of Strong CYP3A Inhibition and P450 Induction on the Pharmacokinetics of Aficamten and the Effect of Aficamten on P-Glycoprotein in Healthy Participants

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of Aficamten in Healthy Chinese Participants: a Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study